Kromatid

Based in the United States, Kromatid is a startup. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

Kromatid provides high-confidence, single-cell genomic characterization and analysis for cell and gene therapy development to assess genomic integrity, structural variants, and transgene integration across the product lifecycle.